TABLE 3.

Immunogenicity of VZV vaccine in immunocompetent, varicella-susceptible subjects

Study (yr) (reference)	No. of doses	Sample sizea	Age group	Test used	Timing of test (wk)	Seroconversion rate (%)
Weibel et al. (1984) (136)	1	468	Children	IAHA/FAMA	8	94
Gershon et al. (1988) (58)	1	184b	Adults	FAMA	4, 8, and 12	82
	2	150b				94
LaRussa et al. (1990) (89)	1	33	Children	FAMA	6	91
White et al. (1991) (142)	1	3,303	Children and adolescents	gpELISA	6	96c
Clements et al. (1995) (28)	1	426	Children	ELISA/gpELISA	6	95
Kuter et al. (1995) (84)	1	490	Adolescents and adults	gpELISA	4	75
	2					99
Asano (1996) (6)	1	2,330	Children	IAHA	4	92
Ngai et al. (1996) (109)	1	1,731	Children	gpELISA	6	98d
	2	718				100
Varis and Vesikari (1996) (130)	1	325	Children	FAMA	5-9	99
Johnson et al. (1997) (76)	1	292	Children	FAMA	6	96

^aExcluding seropositive individuals.

^bSubjects were tested after each dose of vaccine in a two-dose protocol (i.e., the sample populations overlap).

^c79% in the 13- to 17-year age group.

^dOnly 86% of “seroconverters” to a single dose of vaccine achieved titers of 5 gpELISA units/ml or above (83).